Yoshio Takemoto1, Rafael J Ramirez2, Kuljeet Kaur2, Oscar Salvador-Montañés2, Daniela Ponce-Balbuena2, Roberto Ramos-Mondragón2, Steven R Ennis2, Guadalupe Guerrero-Serna2, Omer Berenfeld2, José Jalife3. 1. Department of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Japan; Department of Internal Medicine, Center for Arrhythmia Research, University of Michigan, Ann Arbor, Michigan. 2. Department of Internal Medicine, Center for Arrhythmia Research, University of Michigan, Ann Arbor, Michigan. 3. Department of Internal Medicine, Center for Arrhythmia Research, University of Michigan, Ann Arbor, Michigan; Centro Nacional de Investigaciones Cardiovasculares Carlos III and CIBERCV, Madrid, Spain. Electronic address: jjalife@umich.edu.
Abstract
BACKGROUND: The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown. OBJECTIVES: This study hypothesized that by reducing atrial dilation and fibrosis in the absence of heart failure, EPL also reduces AF burden and prevents AF perpetuation. METHODS: The authors conducted a randomized controlled study in 34 sheep that were atrially tachypaced (13 ± 1 week). They compared daily oral EPL (n = 19) versus sugar pill (SP) treatment (n = 15) from the start of tachypacing. The endpoint was a continuous 7-day stretch of persistent AF (n = 29) or completion of 23 weeks tachypacing (n = 5). RESULTS: EPL significantly reduced the rate of left atrial dilation increase during AF progression. Atria from EPL-treated sheep had less smooth muscle actin protein, collagen-III expression, interstitial atrial fibrosis, and cell hypertrophy than SP-treated sheep atria did. However, EPL did not modify the AF-induced increase in the rate of dominant frequency and ion channel densities seen under SP treatment, but rather prolonged the time to persistent AF in 26% of animals. It also reduced the degree of fibrillatory conduction, AF inducibility, and AF burden. CONCLUSIONS: In the sheep model, EPL mitigates fibrosis and atrial dilation, modifies AF inducibility and AF complexity, and prolongs the transition to persistent AF in 26% of animals, but it does not prevent AF-induced electrical remodeling or AF persistence. The results highlight structural remodeling as a central upstream target to reduce AF burden, and the need to prevent electrical remodeling to avert AF perpetuation.
BACKGROUND: The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown. OBJECTIVES: This study hypothesized that by reducing atrial dilation and fibrosis in the absence of heart failure, EPL also reduces AF burden and prevents AF perpetuation. METHODS: The authors conducted a randomized controlled study in 34 sheep that were atrially tachypaced (13 ± 1 week). They compared daily oral EPL (n = 19) versus sugar pill (SP) treatment (n = 15) from the start of tachypacing. The endpoint was a continuous 7-day stretch of persistent AF (n = 29) or completion of 23 weeks tachypacing (n = 5). RESULTS:EPL significantly reduced the rate of left atrial dilation increase during AF progression. Atria from EPL-treated sheep had less smooth muscle actin protein, collagen-III expression, interstitial atrial fibrosis, and cell hypertrophy than SP-treated sheep atria did. However, EPL did not modify the AF-induced increase in the rate of dominant frequency and ion channel densities seen under SP treatment, but rather prolonged the time to persistent AF in 26% of animals. It also reduced the degree of fibrillatory conduction, AF inducibility, and AF burden. CONCLUSIONS: In the sheep model, EPL mitigates fibrosis and atrial dilation, modifies AF inducibility and AF complexity, and prolongs the transition to persistent AF in 26% of animals, but it does not prevent AF-induced electrical remodeling or AF persistence. The results highlight structural remodeling as a central upstream target to reduce AF burden, and the need to prevent electrical remodeling to avert AF perpetuation.
Authors: Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Karl Swedberg; Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Harry Shi; John Vincent; Bertram Pitt Journal: J Am Coll Cardiol Date: 2012-05-01 Impact factor: 24.094
Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: Raphael P Martins; Kuljeet Kaur; Elliot Hwang; Rafael J Ramirez; B Cicero Willis; David Filgueiras-Rama; Steven R Ennis; Yoshio Takemoto; Daniela Ponce-Balbuena; Manuel Zarzoso; Ryan P O'Connell; Hassan Musa; Guadalupe Guerrero-Serna; Uma Mahesh R Avula; Michael F Swartz; Sandesh Bhushal; Makarand Deo; Sandeep V Pandit; Omer Berenfeld; José Jalife Journal: Circulation Date: 2014-01-24 Impact factor: 29.690
Authors: Narat Srivali; Anwar C Chahal; Meghna P Mansukhani; Jay Mandrekar; Virend K Somers; Sean M Caples Journal: J Clin Sleep Med Date: 2019-10-15 Impact factor: 4.062
Authors: Alba Alvarez-Franco; Raquel Rouco; Rafael J Ramirez; Guadalupe Guerrero-Serna; Maria Tiana; Sara Cogliati; Kuljeet Kaur; Mohammed Saeed; Ricardo Magni; Jose Antonio Enriquez; Fatima Sanchez-Cabo; José Jalife; Miguel Manzanares Journal: Cardiovasc Res Date: 2021-06-16 Impact factor: 13.081
Authors: Nathan C Denham; Charles M Pearman; George W P Madders; Charlotte E R Smith; Andrew W Trafford; Katharine M Dibb Journal: Front Physiol Date: 2021-06-15 Impact factor: 4.566